Glaxo settles multi-state off-label marketing probe with $105M fine

Save

GlaxoSmithKline's latest penalty for improper marketing practices may seem little more than a slap on the hand–except that it's coming at the worst possible time for the embattled British drugmaker. GSK agreed to pay $105 million to settle charges in California, New York, Texas and more than 40 other states that it illegally promoted its asthma drug Advair and antidepressants Wellbutrin and Paxil.